Britain’s Ark Therapeutics Plc said on Monday its cancer treatment had been found to be highly effective in stopping tumour development using only one tenth of the usual chemotherapy dose.

The biotechnology company said thanks to its DNA-based drug-targeting technology Scavidin treatments such as radiation or chemotherapy could be given in lower doses to reduce side-effects.

“These results indicate that Scavidin has the potential both to improve the therapeutic effect and to reduce the unpleasant side-effects of a wide variety of drugs,” Chief Executive Nigel Parker said in a statement.

The biotechnology has “enormous potential” across many disease areas, the group added.

Shares in Ark Therapeutics closed at 93-1/2 pence on Friday, valuing the group at about 119 million pounds ($207 million).